Genetic polymorphisms of TNF-α, VEGF, and UGT1A9 genes have been reported to be a link between HFSRs in patients with hepatocellular carcinoma treated with sorafenib [30]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.